Literature DB >> 19960174

Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Erik C Gunther1, Stephen M Strittmatter.   

Abstract

Prefibrillar oligomers of the beta-amyloid peptide (A beta) are recognized as potential mediators of Alzheimer's disease (AD) pathophysiology. Deficits in synaptic function, neurotoxicity, and the progression of AD have all been linked to the oligomeric A beta assemblies rather than to A beta monomers or to amyloid plaques. However, the molecular sites of A beta oligomer action have remained largely unknown. Recently, the cellular prion protein (PrP(C)) has been shown to act as a functional receptor for A beta oligomers in brain slices. Because PrP(C) serves as the substrate for Creutzfeldt-Jakob Disease (CJD), these data suggest mechanistic similarities between the two neurodegenerative diseases. Here, we review the importance of A beta oligomers in AD, commonalities between AD and CJD, and the newly emergent role of PrP(C) as a receptor for A beta oligomers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960174      PMCID: PMC2846635          DOI: 10.1007/s00109-009-0568-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  82 in total

1.  Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease.

Authors:  Laura Debatin; Johannes Streffer; Markus Geissen; Jakob Matschke; Adriano Aguzzi; Markus Glatzel
Journal:  Neurodegener Dis       Date:  2008-03-18       Impact factor: 2.977

Review 2.  Amyloid beta-protein assembly and Alzheimer disease.

Authors:  Robin Roychaudhuri; Mingfeng Yang; Minako M Hoshi; David B Teplow
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

3.  Stress-protective signalling of prion protein is corrupted by scrapie prions.

Authors:  Angelika S Rambold; Veronika Müller; Uri Ron; Nir Ben-Tal; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

4.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Authors:  Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

Review 5.  Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.

Authors:  Dennis J Selkoe
Journal:  Behav Brain Res       Date:  2008-02-17       Impact factor: 3.332

6.  Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease.

Authors:  Ying Liu; Mi-Jeong Yoo; Alena Savonenko; Wanda Stirling; Donald L Price; David R Borchelt; Laura Mamounas; W Ernest Lyons; Mary E Blue; Michael K Lee
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

7.  APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.

Authors:  Anatoly Nikolaev; Todd McLaughlin; Dennis D M O'Leary; Marc Tessier-Lavigne
Journal:  Nature       Date:  2009-02-19       Impact factor: 49.962

8.  Tauopathy in human and experimental variant Creutzfeldt-Jakob disease.

Authors:  G Giaccone; M Mangieri; R Capobianco; L Limido; J J Hauw; S Haïk; P Fociani; O Bugiani; F Tagliavini
Journal:  Neurobiol Aging       Date:  2007-06-08       Impact factor: 4.673

9.  Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Authors:  Clive Holmes; Delphine Boche; David Wilkinson; Ghasem Yadegarfar; Vivienne Hopkins; Anthony Bayer; Roy W Jones; Roger Bullock; Seth Love; James W Neal; Elina Zotova; James A R Nicoll
Journal:  Lancet       Date:  2008-07-19       Impact factor: 79.321

10.  Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series.

Authors:  T E F Webb; M Poulter; J Beck; J Uphill; G Adamson; T Campbell; J Linehan; C Powell; S Brandner; S Pal; D Siddique; J D Wadsworth; S Joiner; K Alner; C Petersen; S Hampson; C Rhymes; C Treacy; E Storey; M D Geschwind; A H Nemeth; S Wroe; J Collinge; S Mead
Journal:  Brain       Date:  2008-08-30       Impact factor: 13.501

View more
  33 in total

1.  Cellular prion protein (PrP(C)) and its role in stress responses.

Authors:  Liang Zeng; Wenquan Zou; Gongxian Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 2.  Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Authors:  Jessica Nasica-Labouze; Phuong H Nguyen; Fabio Sterpone; Olivia Berthoumieu; Nicolae-Viorel Buchete; Sébastien Coté; Alfonso De Simone; Andrew J Doig; Peter Faller; Angel Garcia; Alessandro Laio; Mai Suan Li; Simone Melchionna; Normand Mousseau; Yuguang Mu; Anant Paravastu; Samuela Pasquali; David J Rosenman; Birgit Strodel; Bogdan Tarus; John H Viles; Tong Zhang; Chunyu Wang; Philippe Derreumaux
Journal:  Chem Rev       Date:  2015-03-19       Impact factor: 60.622

3.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

4.  Neuroimmunoendocrine regulation of the prion protein in neutrophils.

Authors:  Rafael M Mariante; Alberto Nóbrega; Rodrigo A P Martins; Rômulo B Areal; Maria Bellio; Rafael Linden
Journal:  J Biol Chem       Date:  2012-08-21       Impact factor: 5.157

5.  Is AD a homogeneous nosologic entity? Yes.

Authors:  P Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-07-05       Impact factor: 3.575

Review 6.  Immunomodulation for prion and prion-related diseases.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

7.  Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Authors:  Erika Chung; Yong Ji; Yanjie Sun; Richard J Kascsak; Regina B Kascsak; Pankaj D Mehta; Stephen M Strittmatter; Thomas Wisniewski
Journal:  BMC Neurosci       Date:  2010-10-14       Impact factor: 3.288

8.  The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers.

Authors:  Nadine D Younan; Claire J Sarell; Paul Davies; David R Brown; John H Viles
Journal:  FASEB J       Date:  2013-01-18       Impact factor: 5.191

9.  Aβ42 Peptide Promotes Proliferation and Gliogenesis in Human Neural Stem Cells.

Authors:  A Bernabeu-Zornoza; R Coronel; C Palmer; M Calero; A Martínez-Serrano; E Cano; Alberto Zambrano; Isabel Liste
Journal:  Mol Neurobiol       Date:  2018-09-27       Impact factor: 5.590

Review 10.  Myelin damage due to local quantitative abnormalities in normal prion levels: evidence from subacute combined degeneration and multiple sclerosis.

Authors:  Giuseppe Scalabrino; Daniela Veber
Journal:  J Neurol       Date:  2013-10-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.